Human Enteroid Core
人肠类核心
基本信息
- 批准号:8855933
- 负责人:
- 金额:$ 15.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-03-15 至 2020-02-28
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAnimal ModelApicalBiological ModelsCategoriesCause of DeathCell LineCellsCessation of lifeChildCoculture TechniquesColonConditioned Culture MediaDevelopmentDiseaseDuodenumEndoscopic BiopsyEngineeringEnsureEnteralFaceFreezingFunctional disorderGenesGoalsGrowthGrowth FactorHumanImmuneImmune systemIndividualIntestinesMeasuresMesenchymalMesenchymeModelingModificationOperative Surgical ProceduresPatientsPhysiologicalPhysiologyPopulationPre-Clinical ModelReagentReproducibilityResearch PersonnelResearch Project GrantsSamplingServicesSeveritiesSmall IntestinesSpecimenSurfaceSystemTechnology TransferTestingTissuesTrainingValidationVillusagedcell typecost effectivegastrointestinal epitheliumhuman diseaseileumimprovedintestinal epitheliumjejunummeetingsmembermicroorganismnovelnovel strategiespathogenpreventresponsethree-dimensional modeling
项目摘要
Project Summary – Core B
Ex-vivo 3-D “mini-intestine” culture systems, termed enteroids, generated from human surgical
specimens or endoscopic biopsies, have been found to recapitulate the multiple cell types that
comprise the crypt-villus axis of the normal intestinal epithelium. The development of these
enteroids has provided an exciting opportunity to advance our understanding of how pathogenic
as well as beneficial microorganisms, many of which can prevent or lessen the severity of
pathogen-induced diarrheal illness, interact with and induce responses from the intestinal
epithelium. Therefore, the long range objectives of the Human Enteroid Core are to (1)
characterize and compare human enteroids generated from three regions of the small intestine
(duodenum, jejunum, ileum) and colon, from different patients to establish their use as models
of human diarrheal diseases, (2) test new approaches to improve the enteroids as a relevant
model of normal intestinal epithelium, and (3) to provide these enteroids and specialized growth
reagents for use in the other projects (Core C, Projects 1, 2, and 3) proposed in this application.
The goal of the Human Enteroid Core is to provide a centralized facility to meet the enteroid
needs of all of the investigators involved in the NAMSED proposal. The specific functions of the
Core will have two functions: a Service component, which will (1) Produce enteroid cultures
from our existing bank for all projects (2) Establish enteroids from select new patient samples
(3) Maintain frozen stocks of all enteroids (4) Passage and differentiate enteroids per requests
(5) Maintain WNT, noggin, and r-spondin producing cells lines and standardized conditioned
media for enteroid culture (6) Routinely test the enteroid lines for differentiation status (7)
Technology transfer through training group members; a Development component, which will (1)
Develop and standardize physiological measures as indicators of enteroid responses (2) Modify
enteroids to enhance or deplete the presence of specific cell types or genes (3) Co-culture with
mesenchymal cells to test for substitution of growth factors and develop novel structural
components (e.g., inversion of the enteroids such that the apical surface faces outward) (4)
Incorporate immune cells to improve the relevance of the enteroid model. The Core will be
responsive to needs of the individual Projects, which may change as the research projects
proceed, as the overall field evolves and as new platforms are engineered in Project 3. New
activities will be developed to meet the needs of our and other NASMED project investigators.
Our goal is complementary and collaborative in these exciting efforts to develop the enteroids
as models to study enteric disease.
项目总结 – 核心 B
离体 3-D“迷你肠”培养系统,称为肠类,由人体手术产生
标本或内窥镜活检,已被发现概括了多种细胞类型
包括正常肠上皮的隐窝绒毛轴。
Enteroids 提供了一个令人兴奋的机会来加深我们对致病性的理解
以及有益微生物,其中许多可以预防或减轻严重程度
病原体引起的腹泻疾病,与肠道相互作用并诱导反应
因此,人类肠样核心的长期目标是(1)
表征并比较小肠三个区域产生的人类肠类物质
来自不同患者的(十二指肠、空肠、回肠)和结肠,以建立它们作为模型的用途
人类腹泻病的研究,(2) 测试改善肠类相关疾病的新方法
正常肠上皮模型,以及(3)提供这些肠样和专门的生长
用于本申请中提出的其他项目(核心 C、项目 1、2 和 3)的试剂。
人类肠类核心的目标是提供一个集中设施来满足肠类
参与 NAMSED 提案的所有研究者的需求 NAMSED 的具体职能。
核心将具有两个功能:一个服务组件,它将 (1) 产生肠菌培养物
从我们现有的银行中用于所有项目 (2) 从选择的新患者样本中建立肠类
(3) 维持所有 Enteroid 的冷冻库存 (4) 根据请求传代和区分 Enteroid
(5) 维持WNT、noggin和r-spondin产生细胞系并标准化条件化
用于肠样培养的培养基 (6) 定期测试肠样细胞系的分化状态 (7)
通过培训小组成员进行技术转让;开发部分,这将 (1)
开发和标准化生理测量作为肠样反应的指标 (2) 修改
肠类增强或消除特定细胞类型或基因的存在 (3) 与
间充质细胞测试生长因子的替代并开发新的结构
组件(例如,肠体反转,使顶端表面朝外)(4)
合并免疫细胞以提高肠样模型的相关性。
响应各个项目的需求,这些需求可能会随着研究项目的进行而变化
随着整个领域的发展以及项目 3 中新平台的设计,我们将继续前进。 新
将开展活动以满足我们和其他 NASMED 项目研究人员的需求。
我们的目标是在这些令人兴奋的开发肠类药物的努力中进行互补和协作
作为研究肠道疾病的模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NOAH Freeman SHROYER其他文献
NOAH Freeman SHROYER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NOAH Freeman SHROYER', 18)}}的其他基金
Mechanisms of telomere-induced disease: Role of intestinal malabsorption, barrier dysfunction and dsybiosis.
端粒诱发疾病的机制:肠道吸收不良、屏障功能障碍和失调的作用。
- 批准号:
10454085 - 财政年份:2022
- 资助金额:
$ 15.06万 - 项目类别:
Mechanisms of telomere-induced disease: Role of intestinal malabsorption, barrier dysfunction and dsybiosis.
端粒诱发疾病的机制:肠道吸收不良、屏障功能障碍和失调的作用。
- 批准号:
10632001 - 财政年份:2022
- 资助金额:
$ 15.06万 - 项目类别:
The Gastrointestinal Experimental Model Systems (GEMS) Core
胃肠实验模型系统 (GEMS) 核心
- 批准号:
10117232 - 财政年份:2020
- 资助金额:
$ 15.06万 - 项目类别:
Mechanisms of intestinal stem cell differentiation and plasticity.
肠道干细胞分化和可塑性的机制。
- 批准号:
9788430 - 财政年份:2018
- 资助金额:
$ 15.06万 - 项目类别:
KLF5 regulation of intestinal development and stem cell homeostasis.
KLF5 调节肠道发育和干细胞稳态。
- 批准号:
8486426 - 财政年份:2011
- 资助金额:
$ 15.06万 - 项目类别:
KLF5 regulation of intestinal development and stem cell homeostasis
KLF5 对肠道发育和干细胞稳态的调节
- 批准号:
8905197 - 财政年份:2011
- 资助金额:
$ 15.06万 - 项目类别:
KLF5 regulation of intestinal development and stem cell homeostasis.
KLF5 调节肠道发育和干细胞稳态。
- 批准号:
8294532 - 财政年份:2011
- 资助金额:
$ 15.06万 - 项目类别:
KLF5 regulation of intestinal development and stem cell homeostasis.
KLF5 调节肠道发育和干细胞稳态。
- 批准号:
8162496 - 财政年份:2011
- 资助金额:
$ 15.06万 - 项目类别:
相似国自然基金
髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
- 批准号:82372496
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
基于中医经典名方干预效应差异的非酒精性脂肪性肝病动物模型证候判别研究
- 批准号:
- 批准年份:2022
- 资助金额:53 万元
- 项目类别:面上项目
利用肝癌动物模型开展化学可控的在体基因编辑体系的研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
雌激素抑制髓系白血病动物模型中粒细胞异常增生的机制
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
无菌动物模型与单细胞拉曼技术结合的猴与人自闭症靶标菌筛选及其机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 15.06万 - 项目类别:
Establishing the pig as a large animal model for studying drug delivery to the inner ear
建立猪作为研究内耳药物输送的大型动物模型
- 批准号:
10705773 - 财政年份:2022
- 资助金额:
$ 15.06万 - 项目类别:
Developing a novel approach to the nonhuman primate placental organoid model
开发非人灵长类胎盘类器官模型的新方法
- 批准号:
10589154 - 财政年份:2022
- 资助金额:
$ 15.06万 - 项目类别:
Developing a novel approach to the nonhuman primate placental organoid model
开发非人灵长类胎盘类器官模型的新方法
- 批准号:
10371545 - 财政年份:2022
- 资助金额:
$ 15.06万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 15.06万 - 项目类别: